Dexanabinol
Chemical compound
From Wikipedia, the free encyclopedia
Dexanabinol (HU-211 or ETS2101[1]) is a synthetic cannabinoid derivative in development by e-Therapeutics plc[2]. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210.[3] Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead as an NMDA antagonist.[4] It therefore does not produce cannabis-like effects, but is anticonvulsant and neuroprotective, and is widely used in scientific research as well as currently being studied for applications such as treating head injury, stroke, or cancer.[5][6][7] It was shown to be safe in clinical trials[8] and is currently undergoing Phase I trials for the treatment of brain cancer[9] and advanced solid tumors.[10]
| |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.201.022 |
| Chemical and physical data | |
| Formula | C25H38O3 |
| Molar mass | 386.576 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Clinical trials
Dexanabinol has been studied in IV administration and oral dosing.[11] e-Therapeutics is evaluating the compound in clinical trials for brain and solid cancers.[12] Phase II studies are planned based on the results of the current trials.
A phase 1b study for hepatocellular carcinoma and pancreatic cancer was started in 2015.[13]
Legal status
HU-211 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971,[14] so the signatory countries to these international drug control treaties are not required by said treaties to control HU-211.
United States
HU-211 is not listed in the list of scheduled controlled substances in the USA.[15] It is therefore not scheduled at the federal level in the United States, but it is possible that HU-211 could legally be considered an analog of Delta-8-THC (one of the THC isomers which is in Schedule I under the designation of "Tetrahydrocannabinols"), and therefore sales or possession could potentially be prosecuted under the Federal Analogue Act.[16]
HU-211 is a Schedule I controlled substance in Alabama.[17]
HU-211 is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[18]
Effective January 1, 2016, HU-211 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."[19]